Scientific Reference
Mazdutide (IBI362 / LY3305677)
Evidence profile: Human Phase 3 evidence
Mazdutide (IBI362 / LY3305677) is a synthetic analogue of oxyntomodulin acting as a dual glucagon-like peptide-1 (GLP-1) and glucagon receptor agonist. Unlike GLP-1-only or GIP/GLP-1 compounds, it engages the glucagon receptor as well, a mechanism examined in the published literature for its distinct contribution to energy balance. Mazdutide is not an approved medicine and remains in clinical development. Supplied strictly as a research compound for laboratory use.
Published Research
GLORY-2 (NCT06164873)
Treatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity: The GLORY-2 Randomized Clinical Trial
Gao L et al. · JAMA · 2026 · Clinical
PMID 42251595 — View on PubMedMazdutide versus dulaglutide in Chinese adults with type 2 diabetes
Guo L et al. · Nature · 2026 · Clinical
PMID 41407860 — View on PubMedMazdutide versus placebo in Chinese adults with type 2 diabetes
Zhu D et al. · Nature · 2026 · Clinical
PMID 41407859 — View on PubMedGLORY-1 (NCT05607680)
Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight
Ji L et al. · The New England journal of medicine · 2025 · Clinical
PMID 40421736 — View on PubMedNCT05623839
Mazdutide reduces body weight in adults with overweight or obesity: A high-dose Phase 1 trial
Bhattachar SN et al. · Diabetes, obesity & metabolism · 2025 · Clinical
PMID 40832785 — View on PubMedEfficacy and Safety of Mazdutide in Chinese Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial
Zhang B et al. · Diabetes care · 2024 · Clinical
PMID 37943529 — View on PubMed